HomeCompareINNMF vs EPRT

INNMF vs EPRT: Dividend Comparison 2026

INNMF yields 1081.08% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INNMF wins by $37306288.12M in total portfolio value
10 years
INNMF
INNMF
● Live price
1081.08%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37306288.18M
Annual income
$31,563,031,594,132.85
Full INNMF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — INNMF vs EPRT

📍 INNMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINNMFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INNMF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INNMF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INNMF
Annual income on $10K today (after 15% tax)
$91,891.89/yr
After 10yr DRIP, annual income (after tax)
$26,828,576,855,012.92/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, INNMF beats the other by $26,828,576,844,098.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INNMF + EPRT for your $10,000?

INNMF: 50%EPRT: 50%
100% EPRT50/50100% INNMF
Portfolio after 10yr
$18653144.12M
Annual income
$15,781,515,803,486.78/yr
Blended yield
84.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

INNMF
No analyst data
Altman Z
45.4
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INNMF buys
0
EPRT buys
0
No recent congressional trades found for INNMF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINNMFEPRT
Forward yield1081.08%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$37306288.18M$63.4K
Annual income after 10y$31,563,031,594,132.85$12,840.73
Total dividends collected$36872092.59M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: INNMF vs EPRT ($10,000, DRIP)

YearINNMF PortfolioINNMF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$118,808$108,108.11$11,205$505.18+$107.6KINNMF
2$1,327,510$1,200,385.03$12,672$682.46+$1.31MINNMF
3$13,955,553$12,535,117.70$14,490$930.48+$13.94MINNMF
4$138,087,992$123,155,549.73$16,786$1,282.69+$138.07MINNMF
5$1,286,637,044$1,138,882,892.71$19,753$1,791.56+$1286.62MINNMF
6$11,294,046,827$9,917,345,190.59$23,677$2,541.64+$11294.02MINNMF
7$93,443,552,038$81,358,921,932.82$29,008$3,672.99+$93443.52MINNMF
8$729,086,740,275$629,102,139,594.15$36,463$5,425.08+$729086.70MINNMF
9$5,367,529,524,068$4,587,406,711,974.06$47,238$8,221.57+$5367529.48MINNMF
10$37,306,288,184,886$31,563,031,594,132.85$63,385$12,840.73+$37306288.12MINNMF

INNMF vs EPRT: Complete Analysis 2026

INNMFStock

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Full INNMF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this INNMF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INNMF vs SCHDINNMF vs JEPIINNMF vs OINNMF vs KOINNMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.